Lupin Partners with Tenpoint to Expand YUVEZZI™ Eye Drop Reach in Europe
Event summary
- Lupin's VISUfarma secures exclusive rights to commercialize YUVEZZI™ in the EU, UK, Switzerland, Norway, and Iceland.
- Tenpoint Therapeutics will receive regulatory and commercial milestone payments, plus tiered royalties on net sales.
- YUVEZZI™ is the first and only once-daily dual-agent eye drop approved for presbyopia in the U.S.
- Lupin aims to strengthen its specialty care strategy and expand its vision care franchise in Europe.
The big picture
This partnership aligns with Lupin's strategy to expand its specialty care business through innovative therapies. The deal underscores the growing demand for presbyopia treatments, a condition affecting nearly 2 billion people globally. Lupin's move to strengthen its vision care franchise in Europe comes as the ophthalmology market continues to evolve with novel therapeutic approaches.
What we're watching
- Regulatory Progress
- The pace at which Tenpoint secures regulatory approvals for YUVEZZI™ in other key regions worldwide.
- Market Penetration
- How Lupin leverages its European commercial operations to drive YUVEZZI™ adoption in the presbyopia segment.
- Revenue Impact
- Whether the tiered royalty structure will generate significant revenue for Tenpoint and Visus.
Related topics